Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Treatment for Cannabis Dependence
NCT00954681Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Aug 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of quetiapine in cannabis use disorder (CUD), sponsored by New York State Psychiatric Institute. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Aug 2009; status: completed.
02
Drugs
quetiapine
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT00954681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00954681.